Trial Profile

A multicenter, randomized, active controlled, open label, platform trial on the efficacy and safety of experimental therapeutics for patients with COVID-19 (caused by infection with severe acute respiratory syndrome coronavirus-2) ACOVACT (Austrian CoronaVirus Adaptive Clinical Trial)

Status: Discontinued

Phase of Trial: Phase II/III

Latest Information Update: 14 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Asunercept (Primary) ; Candesartan cilexetil (Primary) ; Chloroquine (Primary) ; Hydroxychloroquine (Primary) ; Immune globulin (Primary) ; Lopinavir/ritonavir (Primary) ; Remdesivir (Primary) ; Rivaroxaban (Primary) ; Tocilizumab (Primary) ; Antihypertensives; Doxazosin; Nitrendipine
Indications COVID 2019 infections; Respiratory insufficiency
Focus Therapeutic Use
Acronyms ACOVACT

27 Jan 2021 Planned End Date changed from 31 Dec 2020 to 31 Mar 2022.
27 Jan 2021 Planned primary completion date changed from 1 Dec 2020 to 1 Dec 2021.
21 Apr 2020 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com